

Date: January 12, 2022  
To: All Island Health Staff and Physicians  
From: David Forbes, Interim Director, Pharmacy Services  
Infection Management Advisory Committee (IMAC)

**RE: sotrovimab injection for COVID-19: Use and Access**

---

**Situation:**

The BC COVID-19 Therapeutics Committee (CTC) revised their clinical practice guidance regarding sotrovimab parenteral injection for the treatment of patients with COVID-19. Sotrovimab may be considered on a case-by-case basis for mildly ill patients. This differs from casirivimab + imdevimab (REGEN-COV) injection, another monoclonal antibody, which is recommended in severely ill patients ([see memo](#)).

**Background:**

Sotrovimab injection is a recombinant, human IgG1 monoclonal antibody that targets the spike protein of SARS-CoV-2. **Sotrovimab is non-Formulary for BC hospitals.**

**Guidance:**

**Sotrovimab 500 mg IV x 1 dose** may be considered for patients who are:

- Outpatients, or inpatients within a nosocomial COVID-19 outbreak, AND
- Mildly ill (not requiring supplemental oxygen, IV fluids, or other physiological support), AND
- Unvaccinated, partially vaccinated, or who may have limited immune response to vaccination, AND
- At high risk of developing severe COVID-19-related complications due to at least one co-morbidity (e.g. obesity, hypertension, kidney disease), AND
- Within 7 days of symptom onset and with no prior COVID-19 infection

\*For detailed criteria please see the BC CTC [Clinical Practice Guide for the Use of Sotrovimab](#).

**Inpatient use is restricted to ordering or approval by an Infectious Disease physician.**

**Outpatient use is restricted to prescribing via the following Clinical Order Set: COVID-19 Sotrovimab IV Outpatient (Module) or on approval by an Infectious Disease Physician.**

Outpatient COVID Therapeutics Clinics (OCTCs) will service patients in the community who have been assessed for sotrovimab injection treatment. A public-facing [Island Health Internet web page](#) was created to describe the outpatient screening, virtual physician visit, and infusion pathway.

To contact an Infectious Disease physician to review sotrovimab, refer to the on-call schedule system: <https://medicalaffairs.viha.ca/oncall/BrowseSchedules/>. Under Infectious Diseases, select ID physician on call for either NRGH, RJH, or VGH Infectious Diseases. If there is no doctor listed for NRGH, please call the RJH contact covering.

See [sotrovimab IV info sheet](#).

**Online COVID Resources:**

[COVID-19 Main Page](#)

[Medication Related Guidance and Recommendations](#)